Press Releases

“Changes in memory and cognitive health can start decades before symptoms appear. That’s why early diagnosis and intervention are crucial to slowing impact.  A new paper co-authored by GAP with our partners at Eli Lilly and Company, “Interchangeability of blood-based biomarkers and PET to identify Alzheimer’s disease Pathology” published in Alzheimer’s & Dementia shows that blood biomarkers (P-tau 217 and Precivity AD) have high agreement with […]

“We’re pleased and proud to report our latest paper using Bio-Hermes-001 data has been published in Alzheimer’s & Dementia. Many thanks to the co-authors who helped to bring this research article to light including Richard Mohs, Douglas Beauregard, Lynne Hughes, Cyndy Cordell, Allan Levey, M.D., Ph.D., Saima Rathore, Nicholas Seyfried, Erik Johnson, Jessie Nicodemus-Johnson, Joshua Christensen, and Robin […]

Washington D.C., Jan 20, 2026, The Global Alzheimer’s Platform Foundation® (GAP) applauds the House and Senate Committees on appropriations releasing their final bipartisan FY2026 Labor–Health and Human Services–Education appropriations bill which increases funding for Alzheimer’s disease and other dementia research.     “Congress’s bipartisan approval of increased funding for neurodegenerative research sends a powerful message to the millions of […]

Spear Bio joins collaborative study focused on new biomarkers designed to improvediagnosis of Alzheimer’s disease and dementias  Washington D.C., Jan 12, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Spear Bio, a biotechnology company pioneering wash-free ultrasensitive immunoassay technology, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform […]

Washington D.C., Jan 9, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, to the Bio-Hermes studies. This collaboration will enhance the unique, observational platform studies that compare blood-based and digital biomarkers across a broad range of clinical […]

Collaboration to Improve Access to Study for Alzheimer’s Disease Las Vegas, Nev. – Dec. 23 2025 – Today, Global Alzheimer’s Platform Foundation® (GAP) and Clinical Neurology Specialists (CNS) announced their collaboration to accelerate Alzheimer’s disease research in Las Vegas. CNS has joined the GAP-sponsored study, Bio-Hermes-002, a unique, observational platform study that compares blood-based and digital biomarkers […]

The Global Alzheimer’s Platform Foundation® (GAP) today issued a statement following the release of top-line updates from two Alzheimer’s clinical trials: Recently, developments in two important Alzheimer’s clinical research studies were reported. The two studies were: Novo Nordisk’s Phase 3 EVOKE and EVOKE+ trials evaluating oral semaglutide, and Johnson & Johnson’s Phase 2b trial evaluating the […]

International non-profit Global Alzheimer’s Platform Foundation expands research network in California to improve access to research opportunities Washington D.C., Oct. 14, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Sun Valley Research Center (SVRC) a private clinical research organization based in Imperial, California, to its global network of over 100 best-in-class research sites. SVRC […]

Strategic collaborations are key to improving the pace and access to research.  Undiagnosed and Overlooked  Everyone knows someone impacted by Alzheimer’s disease, as it affects an estimated 55 million people worldwide. What is often overlooked is the shocking number of people who remain undiagnosed due to fear of going to a doctor, lack of access […]

Mission Viejo, Aug 12, 2025— Brain health is being taken on the road in Mission Viejo with a Mobile Research Unit that will tour the West Coast to improve accessibility to brain health education and services. The Mobile Research Unit made its debut on August 9 with a ribbon cutting with The Healthy Brain Clinic […]

Florida Mobile Research Unit Launched with Axiom Brain Health at New Mt. Zion Baptist Church     Tampa, FL Aug 6, 2025— Brain health is being taken on the road in Tampa as Axiom Brain Health launched a new Florida-based mobile research unit that will tour the state, to improve accessibility to brain health education and […]

Data from Most Deeply Characterized Cohort Across Alzheimer’s Disease Released byGlobal Alzheimer’s Platform Foundation and Alzheimer’s Disease Data Initiative Washington D.C., July 31, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated from the Bio-Hermes-001 study are now publicly available. This release […]

Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]

Showcase on Bio-Hermes Data Challenge and Poster Presentation to Take Place at the Alzheimer’s Association International Conference (AAIC) Washington D.C., July 23, 2025- The Global Alzheimer’s Platform Foundation® , (GAP) will have a poster presentation and a Featured Research Session at the 2025 Alzheimer’s Association International Conference (AAIC) being held in Toronto, Canada. Poster Presentation […]

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias  Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study […]

For immediate release:   Contact: media@globalalzplatform.org Washington D.C., May 20, The Global Alzheimer’s Platform Foundation® (GAP) applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio invitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s—a critical […]

International non-profit expands research network to Hawaii to improve access to research opportunities Washington D.C., May. 13, 2025- Global Alzheimer’s Platform Foundation ® (GAP) announces the addition of Hawaii Pacific Neuroscience a leading private clinical research organization based in Honolulu, Hawaii, to its global network of over 100 best-in-class research sites. Hawaii Pacific Neuroscience addresses the […]

GAP regrets to report that Dr. Neil Buckholtz, a valued member of the GAP Board of Directors, passed away earlier this week. Neil was a research pioneer that made singular contributions to improving the infrastructure and science pursuing therapies and cures for Alzheimer’s and related dementias.  Neil pursued several medical and health disciplines, receiving his […]

Global Researchers Recognized for Trailblazing Projects in First-of-Its-Kind Data Competition Washington D.C., Mar. 27, 2025 – International non-profit organization The Global Alzheimer’s Platform Foundation® (GAP) in collaboration with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC) and the Alzheimer’s Disease Data Initiative proudly announced four winners of the Bio-Hermes Biomarker Data Challenge  at the first Data […]

The Global Alzheimer’s Platform Foundation® (GAP) – which is focused on global game-changing dementia research working with the Scottish Funding Council’s Brain Health Alliance for Research Challenges (ARC)  proudly announces the first-of-its-kind Data Challenge Summit which will unveil the results stemming from the Bio-Hermes-001 Biomarker Data Challenge. The research competition was launched in February of 2024 to allow researchers early access […]

 International non-profit expands research network to Syracuse to improvecommunity access to research opportunities Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, […]

Washington D.C., Feb. 28, 2025 -The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025 GAP-Net Site Optimization Conference in Miami, Florida. GAP’s Citizen Scientist Awards (CSA) celebrate the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s […]

Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend. John Dwyer, the […]

Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]